CTXR
Citius Pharmaceuticals Inc. Common
stockNASDAQ
citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.55 | 2026-09-28 | -3.08% | 0.387 |
| 1M | 0.59 | 2026-09-04 | -9.46% | 1.026 |
| 3M | 0.61 | 2026-07-06 | -12.41% | 2.625 |
| 6M | 0.86 | 2026-04-06 | -38.12% | 2.106 |
| 1Y | 1.37 | 2025-10-03 | -61.16% | 2.605 |
| 2Y | 10.85 | 2024-10-04 | -95.10% | — |
| 5Y | 48.75 | 2021-10-04 | -98.91% | 1.157 |
Citius Pharmaceuticals Inc. Common (NASDAQ:CTXR) stock price today is $0.53, and today's volume is 80,508. CTXR is down 1.499% today. The 30 day average volume is 298,443. CTXR market cap is $14.61M with 27.45M shares outstanding.